en.Wedoany.com Reported - Xcovery Holdings has entered into a collaboration agreement with commercialization services provider EVERSANA to support and expand the commercial launch of the ALK-positive lung cancer drug ENSACOVE in the U.S. market. The drug is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK inhibitor. ENSACOVE is now available in the United States.

Under the agreement, EVERSANA will provide Xcovery with end-to-end commercialization services spanning market access, a commercial team, and a medical team to enhance patient access to the ALK-positive lung cancer drug across the United States.

Dr. Giovanni Selvaggi, Chief Medical Officer of Xcovery Holdings, stated: “The approval of ensartinib marks a significant milestone in our mission to advance precision oncology. As we expand the launch of ENSACOVE in the U.S., we are focused on ensuring patients and healthcare providers receive the support they need. EVERSANA brings experienced, scalable commercialization capabilities, and we are pleased to collaborate with them to expand patient access.”

Gregory Skalicky, President of EVERSANA, said: "EVERSANA was founded to help companies like Xcovery implement more impactful commercial strategies, enabling more patients to benefit from therapies like ensartinib."

The ALK-positive lung cancer drug ENSACOVE, co-developed by Xcovery and Betta Pharmaceuticals, will see its commercial operation capabilities in the U.S. market strengthened through this collaboration.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com